TuHURA Biosciences, Inc. borrowed an additional $650,000 under its existing revolving credit facility with Parkview Holdings One LLC on September 21, 2026. The loan agreement, originally entered into in April 2026, provides a maximum availability of $50 million and matures on April 21, 2031. The company intends to use the proceeds for general corporate purposes. TuHURA Biosciences operates as a clinical-stage biotechnology company focused on developing therapies for rare diseases.
